Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of GW870086X in Persistent Asthma
NCT01245426Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2010
- Primary completion
- Jul 2011
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of GW870086 in asthma (5 arms), sponsored by GSK. Primary endpoint: Forced Expiratory Volume in 1 Second at Day 28. Started Dec 2010; status: completed.
02
Drugs
GW870086
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01245426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01245426.